Member Info for NickE

Pokerchips , good to have a civil discussion with you . There are of course bear points and bull points with the Company as indeed applies to every stock - particularly on AIM. I think the bull points over the next six months outweigh the negatives with MXC but respect your views.

In terms of revenues and timescales, they may be a bit optimistic but I see the CEO anticipate CimetrA being on sale this year.

With such poor prognosis for most brain cancer patients I hope and expect the Company will be allowed to accelerate the development where, relatively early stage though it may be, they state "we have been able to achieve amazing results on CBG and CBD in targeting the stem cells" without having to do any invasive surgery. See below:-

https://cannabiswealth.co.uk/2021/07/29/mgc-pharma-discusses-drug-delivery-innovation/

That's fine but you tried to suggest that the results would not be released as there had to be a three month evaluation. That's misleading as there will be results about one month following the completion of the main trial. The three months, as you reference in your subsequent post, is a sub trial to monitor post Covid syndrome symptoms. What I guess is colloquially known as 'long Covid'.

I normally buy and hold but I don't necessarily see this as a long year or so hold but a reasonable risk/reward for the coming months of this year . That's based on the good results from phase two of the CimetrA trial and a decent prospect of a favourable phase 3 clinical trial.

There is also the phase 2 results CogniCann(R) - Phase II clinical trial evaluating the impact on dementia and Alzheimer's Disease patients. That should complete Q4.

Plenty of newsflow to come. I am not a big fan of investing in Company's with CLN's but any positive news from the CimetrA trial should outweigh that negative. I wouldn't be surprised to see a run-up in anticipation of the CimetrA results.

That's fine but you tried to suggest that the results would not be released as there had to be a three month evaluation. That's misleading as there will be results about one month following the completion of the main trial. The three months, as you reference in your subsequent post, is a sub trial to monitor post Covid syndrome symptoms. What I guess is colloquially known as 'long Covid'.

I normally buy and hold but I don't necessarily see this as a long year or so hold but a reasonable risk/reward for the coming months of this year . That's based on the good results from phase two of the CimetrA trial and a decent prospect of a favourable phase 3 clinical trial.

There is also the phase 2 results CogniCann(R) - Phase II clinical trial evaluating the impact on dementia and Alzheimer's Disease patients. That should complete Q4.

Plenty of newsflow to come. I am not a big fan of investing in Company's with CLN's but any positive news from the CimetrA trial should outweigh that negative. I wouldn't be surprised to see a run-up in anticipation of the CimetrA results.

Pokerchips, there appears to be some guesswork / misinformation in your post. From the announcement on 7th July. They have announced the trial has begun so they are on track. The timeframes may be a bit tight depending on recruitment but not as extended as you have indicated. They have multiple trial sites in Israel and Brazil for recruitment. Regardless, it looks like results in Autumn this year.

From the announcement dated 7th July :-

" Expected duration: The trial is expected to commence in the coming week and conclude around September 202 1 with
results then available in October 2021. "

I can see this having a decent run as the herd move in for the phase 3 trial results in the Autumn. Should be an update or two prior to starting as they get the trial recruitment numbers. Now they have the centres in Brazil they should be able to reach the numbers reasonably quickly.

It's an important trial from a global health perspective and, accordingly, it should get plenty of media attention as well.

Very short trial (about one month I believe) and relatively low risk given all the favourable results so far, although no phase 3 is without risk of course. Hard to say where it could move to if successful in the trial, but back to the highs from the UK listing levels would be nice.

Yes the FD might as well have been wearing a hoodie and headphones. He was slumped in his chair and tapping on his phone for the entire meeting. I couldn't believe it and the brevity of his answers and disinterest either indicates an embarrassment with his poor English or just pure arrogance and inappropriate behaviour for someone who represents a publicly listed company.

MR did try to explain the absence of any upbeat tone by saying STAR wants to under promise and over deliver and it had been a difficult time for everyone due to Covid-19. He said they had previously done the opposite 'been there and done that before' and implied that approach back-fired. He also explained that there were pandemic issues such as difficulty with supplies that meant things had been difficult. He balanced that by saying hopefully that will change in due course. I think with the previous slap on the wrist for dubious accountancy reporting he now errs on the side of caution. He wouldn't be happy with the Rosenberg name being associated with anything untoward and wants to come across as circumspect and small c conservative. Also, he doesn't have much skin in the game although he may have a decent slug of options.

The negative tone is undoubtedly depicting past and present but they should have balanced that with what looks like potentially good prospects for a lokies contract going forward. On that product was there really any need for MR to say the DHL pilot trials are very, very early stage? Maybe having mentioned Bosch and the United Nations potential contracts previously and nothing material developing he is under-stating for the same reasons as above; a desire to be a cautious realist and hopefully under-promising and over delivery?

The issue of STAR being unduly negative might be for the above 'realism' reasons but they have to watch their negative tone as cynics might point to the fact that two thirds of salaries / fees of the Chairman are being paid in shares each month. Obviously the lower the share price the more shares received. I doubt that but ...

STAR have been brilliant at managing cash resources and maintaining superb R&D technical innovations and upgrades with such limited funds. Cash must be tight now so I'd be very disappointed if they raised at current levels with such a downbeat statement and presentation. I'd like directors to take part but the downbeat tone wouldn't sit well with me if they did. Perhaps they will await the potential Lockies contract and, if that materialises, then they would either not have to raise or could do so at a significantly higher price. Regardless, whilst conscious of costs and continuity, they need a decent PR company and perhaps a more dynamic chairman who can give a more upbeat tone. The Company has to be worth a lot more for its IP and product range and surely even on a small revenue multiple has to be worth much more and be of interest to third parties.

Very unprofessional presentation. Wasn't impressed with seeing the FD slumped in his chair playing on his 'phone. What on was he doing? When Michael Rosenberg tried to engage him he gave monosyllabic disinterested answers. The statement was so poorly worded as if they wanted the share price to go down.

Before the meeting they were discussing share holdings and one of the board told Michael R he had 1.5m shares. MR questioned that and they were mumbling something about more being in nominee.

They need someone PR savvy to help them out unless they actually temporarily want a lacklustre share price to get a funding away. Rosenberg did his best but he doesn't have much skin in the game and, without wishing to be harsh, is past his sell by date and doesn't impart the right image for a high tech innovative company Company. I think he probably writes the newsflow as well as the others have broken English at best. Perhaps the board will participate in any raise and we might get some more positive vibes after then. The way this was done goes way below amateur and contrasts with the excellent product innovation and success on a tight budget that they have achieved. They must have done a much better presentation to DHL. Very disappointing and odd.

They say there will be no AGM presentation but presumably they will take questions via Zoom after the formal business?

No, it's actually about £50m m/cap with currently 2,319,502,595 shares in issue.

Interesting company but with a lot of 'unsticky' shares issued to various parties causing an overhang with more shares to be issued imminently. The parties who receive the shares appear to have an interest in the share price being as low as possible as the number of shares they receive is based on a 10 day average share price. Timing entry here could pay off but it looks like the overhang will be around for about 9 months until all the shares for the acquisition have been issued. Last issue looks to be May 2022. That's my reading of it anyway but happy to be corrected and dyor etc. Who knows, great news from clinical trials could change what looks like the trend and overhang.

The imminent new shares relate to the recent GM announcement and the issue of shares in stages for the acquisition of MediCaNL for AU $6m as detailed in the April acquisition rns.

"The consideration for the Acquisition is $6,000,000 in MXC shares, based on the volume weighted average price per share of the Company calculated on a 10-day VWAP from settlement, with 30% of the consideration shares to be issued at settlement (under the Company's existing Listing Rule 7.1 placement capacity) and the remaining 70% (the Deferred Consideration) to be issued in instalments as follows (subject to shareholder approval):

(a) 20% on the date which is 4 months from the date of settlement;

(b) 20% on the date which is 7 months from the date of settlement;

(c) 20% on the date which is 10 months from the date of settlement; and

(d) 10% on the date which is 13 months from the date of settlement, "

I contacted the Company's advisors (Luther Pendragon) about the absence of an rns on the covid-19 detection machine trials in the context of the CEO, Dr Basu, saying results would be forthcoming in the 'coming days' and had this reply copied below. Whilst , as you'd expect, no specific date is given, I think it bodes well for a potential release of the Covid trial results either with the financials on the 14th or close to that date. It's also telling that clips emphasising the initial current positives from the trial were also detailed in the reply.

"Kromek is committed to keeping shareholders abreast of significant developments and fully intends to provide an update on the trials and the status of the bio-threat detection solution via RNS as appropriate.

Over the last few weeks, the company has commented on the positive results being achieved at trials in a number of locations: Newcastle Airport, Teeside Airport, Durham School and St Mary’s ****erton School. You can find further details in news clips linked below.

https://youtu.be/LqvE2Mvhy_8

https://youtu.be/Eb-p-MDgjAg

https://youtu.be/y6wohFSPHSY

Excellent summary Wil. It has been a long and patience-testing investment. At current levels, however, it looks one of the least risky potential multi-baggers on the market:-

* Cash sorted for approximately a year,

* The loan sorted

* Solid and astute backers such as Aberdeen Asset Management retiring CEO, Martin Gilbert. A compelling endorsement if ever there was one

* Covid19 and social distancing making Min's project an enticing investment in an idyllic location for the high net worth market.

* Greece being one of the more stable and attractive places to invest with the Govt placing a particular emphasis on encouraging high-end tourism projects.

8.75p would be nice but the project value could be worth up to 100m based on past comments by those close to the project. That would give upside to circa 18p. I don't envisage that.

I like to be circumspect and keep expectations in check and, who knows, there may be a bit more dilution. The figures point to an ultimate 8.75p plus but given the history and current share price, my own target is 5p to 6p. Regardless, the risk/reward appears highly compelling.

Yes, a bit of an odd conspiracy given the miniscule volume - particularly the bit about Bosch. A couple of posters have researched some interesting factual research snippets that is supportive of potentially positive developments with Bosch. For me, that's one of the pluses of a forum rather than 24,000 repetitive one-liners from the likes of our friend Dougal. If I was a conspiracy theorist (which I am not) I'd think that the sellers or traders currently out of the stock are those that don't want to hear factually based potentially positive developments about a partner to a 4m m/cap company that happens to be a global giant.

I think a more likely 'conspiracy theory' is that the MM's like to keep a flat book for small caps on low volume days in volatile markets hence the wide spreads and trading patterns.

Good to hear your security company is doing well Ed, if it's representative of the sector as a whole then that bodes well for Lokies and general security via tracking.

It's been interesting to see how once any stock gets associated with the prospect of Corinavirus related trade then the share price takes off with momentum. In the main, this has been the obvious companies such as those developing or being involved with potential vaccines, N4P & SNG and also the cleaning companies e.g. (BYOT). We'll see if security and tracking companies follow suit. If so, then STAR could be re-rated more than we might envisage. There will be a lot of investors looking for the next sector to benefit and moving their profits from the sectors mentioned. We'll see.

The fact that the relationship with Bosch is hopefully going to the next stage is also very encouraging as well. I'd still like to see an investment from the Bosch venture cap fund. It's not needed given the director loans, but not needing funds puts STAR in a solid position of financial strength to negotiate any potential Bosch investment.

Excellent news and a real vote of confidence from those at the sharp end who know all there is to know about the business going forward. The 4m warrants at 1.5p also provide a ready source of funding and even more management alignment for some of the anticipated large orders (Lokies etc.) that have already been alluded to by the Company.

At a time when personnel can't always secure sites and goods with a physical presence, a remote locking system with security alerts should be in demand. It also seems clear that coronavirus is going to increase demand for tracking goods. At some stage the Company will be bought out I think but at a multiple of current levels.

Absolutely spot on GLR, it's an emphatic endorsement of future prospects for any stock to finish blue on a day like today.

To answer your question Dougal, 'how certain are you?' the exact answer is 82.2345% (rounded down to four decimal places). That's a FACT, mainly on the basis I have put 'fact' in capital letters so it's therefore indisputable. I hope that helps.

Reiterated the forecast circa $10m for 2021 which equates to exponential growth. Staggering that a tech company with exponential growth, good EBITDA profit, blue-chip clients and an array of products (eggs not just in one basket) is valued with such a lowly m/cap. At some stage, there will be a significant re-rating, a strategic investment by the likes of the Bosch Venture Capital fund or perhaps even takeover. Good to see another director do the interview and he came across very well. Hard to say what will trigger a re-rating but it might just be something like a decent Lokies contract and that prospect has already been flagged up by STAR.

All coming together very nicely it seems. From the rns, Starcom received $200k for just 'a few hundred orders' within a trial period. Clearly the orders were kept to a minimal number as the trial objective was to assess the quality of the product.

The trial has obviously been very successful. It would be interesting to know what the ball-park orders expectation are and what 'a significant increase' will mean, but I would assume a multiple of a few hundred orders now the trial has finished. Perhaps it's too simplistic to say that equates to multiples of $200k as that sum might include a trial fee but I think it's going to be a very meaningful addition to turnover. So, it's yet another sector to add to Zero that is flagged up as likely to have additional meaningful revenues this year.

Starcom now has a product that has passed a trial successfully and is third party endorsed for its quality and safety: "CubeMonk has received very positive feedback from the end-users in the trial'). So, as the rns implies, some additional airlines are likely to enter into contracts as well given the product has passed its trial period very successfully. Allenby might have to up their revenue projections for 2020 I think.

Riddler, I don't think that and I said as such, I merely pointed out the clarity of wording isn't as crystal clear as it should be. I'm not sure if Avi Hartmann writes the rns's but, good CEO that he is, his English is far from perfect. Starcom do the important things well, but PR and highlighting their progress could be better.

I also hope and believe Lokies is the most innovative smart lock and will pick up sales outside Russia. Since you believe likewise, why didn't you assign more than $2m for Lokies in 2020 given that Starcom's projected figure relates solely to expectations from Russia?

Yes, the $2m for 2020 is solely linked to the Russian distributor which is exceptionally good in itself if achieved.

The only issue is whether the Russian distributor has global exclusivity or whether the exclusivity is confined to Russia. The wording, to me at least, isn't crystal clear:- "The agreement is for three years and provides exclusivity to the distributor in Russia, subject to them meeting certain targets."

Do they mean the distributor residing in Russia and therefore exclusivity full stop (global)? Or, alternatively, do they mean the distributor with rights solely for the Russian territory?

If it is the latter and they are targetting $2m solely for Russia then clearly the possibility of much higher revenues for Lokies exists for 2020. I think there is some legislation related to transporting goods on Russian Railways that is helpful in getting Lokies contracts within Russia hence Starcom's focus but, regardless, the Company's positivity about prospects for Russia bodes well for other territories as well.

This tweet (copied below) caught my eye and might be worthy of further research. I don't think STAR have ever announced that the potential U.N. deal has ever been concluded with the other competitor. I wouldn't put 'potential U.N. deal' towards the top of the list of the bull points for STAR simply because it was so long ago and nothing has materialised, however, the tweet below is interesting :-

#star #starcom Pretty sure the contract in Ukraine is with osce(part of UN /European peacekeeping initiative ).We were awarded a contract with them in 2016 .So maybe the U.N. deal is not dead?